Table 3.
EQ-5D-5L and WPAI results
| G551D/IVA patient group | F508del/SOC patient group | P value | |
|---|---|---|---|
| EQ-5D-5L | |||
| Index score (0–1), n; LS mean (SE) | 72; 0.90 (0.02) | 137; 0.81 (0.02) | < 0.01 |
| VAS score (0–100), n; LS mean (SE) | 72; 75.7 (1.8) | 135; 70.0 (1.4) | 0.0136 |
| WPAI | |||
| School, na | 41 | 53 | |
| Productivity loss, n; LS mean (SE)b | 27; 24.62 (6.69) | 32; 34.57 (6.73) | 0.3242 |
| Daily activities, n | 70 | 135 | |
| Activity impairment, LS mean (SE)c | 21.63 (2.95) | 28.30 (2.19) | 0.08 |
CF Cystic fibrosis, EQ-5D-5L EuroQol 5-dimensions 5-level questionnaire, IVA Ivacaftor, LS Least squares, SE Standard error, SOC Standard of care, VAS Visual analog scale, WPAI Work Productivity Activity and Impairment Questionnaire
aA total of 29 students were excluded because they were not in school over the past 2 weeks for reasons other than CF or had missing data
bProductivity loss: combination of absenteeism and presenteeism representing the percentage of overall impairment due to CF
cActivity impairment: percentage impact of CF on daily activities